Особенности системы гемостаза у больных терминальной почечной недостаточностью
Диссертация
Проведение единственной процедуры, ГДнесмотряна адекватнуюантикоагуляцию гепаринами (нефракционированным и низкомолекулярным), сопровождалось активациейвнутрисосудистого свертываниякрови с повышением уровня д-димера у 20% больных, получавших НФГ, и у 38,5% — НМГ. Постоянное применение во время процедуры ГД низкомолекулярного гепарина, в сравнении с нефракционированным гепарином, отличалось… Читать ещё >
Список литературы
- Алексеева JI.A., Рагимов А. А. ДВС-синдром. Москва, ГЭОТАР — Медиа, 2010- 61.
- Баркаган З.С., Момот А. П. Диагностика и контролируемая терапия нарушений гемостаза. Москва, «Ньюдиамед», 2001−420.
- Долгов В.В., Свирин П. В. Лабораторная диагностика нарушений гемостаза. Тверь, Триада, 2005- 199.
- Дуничева О.В. Роль регистра в организации помощи больным хронической почечной недостаточностью. Автореферат дисс. кандидата мед наук. Новосибирск, 2006.
- Земченков А.Ю., Команденко М. С., Константинов Ю. В. и соавт. Санкт-Петербургский регистр больных на диализной терапии, Санкт-Петербург, 1999.
- Ильин А.П., Богоявленский В. Ф. Тромбофилия при гемодиализе у больных хронической почечной недостаточностью. Пособие для врачей. 2-е изд. Казань- 2001.
- Лашутин C.B. Длительное лечение анемии эритропоэтином у больных с хронической почечной недостаточностью на программном гемодиализе. Автореф. дисс. кандидата мед наук. Москва, 1993- 45.
- Шило В.Ю., Козлова Т. В., Денисов А. Ю. Опыт применения фрагмина у больных на программном гемодиализе. Фарматека, 2005- 6:1−5
- Adler S., Szczech L., Qureshi A. et al. IgM anticardiolipin antibodies are associated with stenosis of vascular access in hemodialysis patients but do not predict thrombosis. Clin Nephrol 2001- 56: 428134.
- AmbuhlP.M., WuthrichR.P., Korte W. et al. Plasma hypercoagulability in haemodialysis patients: impact of dialysis and anticoagulation. Nephrol Dial
- Transplant 1997- I2 (l 1): 2355−2364."
- Ando M., Iwata A., Ozeki Y. et al. Circulating platelet-derived microparticles with procoagulant activity may be a potential cause of thrombosis in uremic patients. Kidney Int 2002- 62:1757−1763.
- Andrassy K., Ritz E. Uremia as a cause of bleeding: Am J Nephrol 1985- 5:313−319.
- Atac B., Yakupoglu U., Ozbek N. et al. Role of genetic mutations in vascular access thrombosis among hemodialysis patients waiting for renal transplantation. Transplant Proc 2002- 34: 2030−2032.
- Attman P.O., Alaupovic P. Lipid and apolipoprotein profiles of uremic dyslipoproteinemia relation to renal function and dialysis. Nephron 1991- 57: 401−410.
- Baskin E., Duman O., Besas N., Ozen S. Hypercoagulopathy in a Hemodialysis Patient: Are Elevations in- Factors VII and: VIII Effective? Nephron 1999−83:180−180.
- Basmadjian- DV, Sefton M.V., Baldwin S^A. Coagulation on biomaterials in flowing blood: Some theoretical considerations. Biomaterials. 1997- 18:1511— 1522.
- Bassilios N., Menoyo V., Berger A. et al. Mesenteric ischaemia in. haemodialysis patients: a case-control study. Nephrol Dial Transplant 2003- 18:911−917.
- Bechar M., Lakke J.P., van der Hem G.K. et. al. Subdural hematoma during long tenn hemodialysis. Arch Neurol 1972- 26:513−516.
- Benigni A., Boccardo P., Galbusera M. et al. Reversible activation defect of the platelet glycoprotein Ilb-IIIa complex in patients with uremia. Am J Kidney Dis 1993−22:668−676.
- Bonomini M., Sirolli V., Merciaro G. et al. Red blood cells may contribute to hypercoagulability in uraemia- via enhanced surface exposure of phosphatidylserine. Nephrol Dial Transplant 2005- 20: 361−366.
- Bonomini M., Sirolli V., Stuard S., et al. Interactions between platelets and leukocytes during hemodialysis. Artif Organs. 1999- 23:23−28.
- Borra S. Gavani S., Rleinfeld M. Giant peptic ulcers in patients with chronic renal failure. Mt Sinai J Med. 1990- 57(2):97−101.
- Borra S., Kleinfeld M. Subscapular liver hematoma in a patient on chronic hemodialysis. Ann Int Med 1980- 93:574−575.
- Brommer E.J.P., Schicht I., Wijngaards G. et al: Fibrinolytic activators and inhibitors in terminal renal insufficiency and in anephric: patients. Thromb Haemost 1984- 52:311−314.
- Buck J., Baker R., Cannaby A.M. et al. Why do patients known to renal services still undergo-urgent dialysis initiation? A: cross-sectional survey. Nephrol Dial Transplant. 2007−22(ll):3240−5.
- Castillo R., Lozano T., Escolar G. et al. Defective platelet adhesion on vessel subendothelium in uremic patients. Blood 1986- 65:337−342.
- Crowther M.A., Clase C.M., Margetts P.J. et al. Low-intensity warfarin issineffective for the prevention of PTFE graft failure in patients on hemodialysis: a randomized controlled trial. J Am Soc Nephrol. 2002 Sep-13(9):2331−7.
- Culp K., Flanigan M., Taylor L., Rothstein M. Vascular access thrombosis in new hemodialysis patients. Am J Kidney Dis. 1995 Aug-26(2):341−6.
- Cunningham J.T. Gastric telangiectasis in chronic hemodialysis patients: a report of six cases. Gastroenterology 1981- 81:1131—1133.
- Daneschvar H.L., Seddighzadeh A., Piazza G., Goldhaber S.Z. Deep vein thrombosis in patients with chronic kidney disease. Thromb Haemost. 2008 Jun- 99(6): 1035−9.
- Defreyn G., Vergara Dauden M., Machin S.J. et al. A plasma factor in uraemia which stimulates prostacyclin release from cultured endothelial cells. ThrombRes 1980- 19:695−699.
- Di Minno G., Martinez J., McKean M. et al. Platelet dysfunction in uremia. Multifaceted defect partially corrected by dialysis. Am J Med 1985- 79:552 559.
- Doherty C.C. Gastrointestinal bleeding in dialysis patients. Nephron 1993- 63 (2): 132−6- discussion 137−9.
- Edwards C., House A., Shahinian V., Knoll G. Sirolimus-based immunosuppression for transplant-associated thrombotic microangiopathy Nephrol Dial Transplant 2002- 17: 1524−1526.
- Eiser A.R. Gastrointestinal bleeding in maintenance dialysis patients. Semin Dial 1988- 1:198−202.
- Eleitheriadis T., Antoniadi G., Akritidou A. et al. A case report of recurrent vascular access thrombosis in a hemodialysis patient reveals combined acquired and inherited thrombophilia. Ther Apher Dial. 2008 Apr- 12(2): 1902.
- Eleftheriadis T., Antoniadi G., Liakopoulos V. S, Stefanidis I. About the effect of low-molecular-weight heparin on platelet function in hemodialysis patients Nephrol. Dial. Transplant. 2009- 24: 1063−1064.
- Erdem Y., Haznedaroglu I.C., Celik I. et al. Coagulation, fibrinolysis and fibrinolysis inhibitors in" haemodialysis patients: contribution of arteriovenous fistula. Nephrol Dial Transplant 1996- 11: 1299−1305.
- Eschbach J.W., Egrie J.C., Downing M.R. et al. Correction of the anemia of end stage renal disease with recombinant human erythropoietin. N Engl J Med 1987- 316: 73−78.
- European best practice guidelines for hemodialysis (part 1). Nephrol Dial Transplant. 2002- 17(7):63−71.
- Falga C., Capdevila J.A., Soler S. et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost. 2007 Oct-98(4):771−6.
- Fass R.J., Copelan E.A., Brandt J.T. et al. Platelet-mediated bleeding caused by broad-spectrum penicillins. J Infect Dis 1987- 155:1242.
- Feldman H.I., Held P.J., Hutchinson J.T. et al. Hemodialysis Vascular Access Morbidity in the United States Kidney Int 1993- 43:1091−1096.
- Fernandez F., Goudable C., Sie P. et al. Low hematocrit and prolonged bleeding time in uraemic patients: effect of red cell transfusions. Br J Haematol 1985- 59:139−148.
- Finelli P.F., Carley M.D. Cerebral venous thrombosis associated with epoetin alfa therapy. Arch Neurol. 2000- 57: 260−62.
- Fitzgerald D.J., Roy L., Catella F., Fitzgerald G.A. Platelet activation in unstable coronaiy disease. N Engl J Med 1986- 315: 983−989.
- Fodinger M., Mannhalter C., Pabinger I. et al. Resistance to activated protein C (APC): Mutation at ARG of coagulation factor V and vascular access thrombosis in hemodialysis patients. Nephrol Dial Transplant 1996−11: 668 672.
- Fox K.A., Antman E.M., Montalescot G. et al. The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial. J Am Coll. Cardiol. 2007 Jun 12- 49(23):2249−55.
- Franchini M. Heparin-induced thrombocytopenia: an update. Thromb J. 2005−3:14.
- Frank R.D., Weber J., Dresbach H. et al. Role of contact system activation in hemodialyzer-induced thrombogenicity. Kidney Int. 2001- 60:1972—1981.
- Fukasawa M, Matsushita K., Kamiyama M. et al. The methylentetrahydrofolate reductase C677T point mutation is a risk factor for vascular access thrombosis in hemodialysis patients. Am J Kidney Dis 2003- 41: 637−642.
- Furie B., Furie B.C. Mechanism of thrombus formation. N Engl J Med 2008- 359:938−49.
- Gaarder A., Jonsen J., Lland S. et al. Adenosine diphosphate in red cells as a factor in the adhesiveness of human blood platelets. Nature 1961 — 192:531 532.
- Gafter U., Bessler H., Malachi T. et al. Platelet count and thrombopoietic activity in patients with chronic renal failure. Nephron 1987- 45:207—210.
- Gallego E., Lopez A., Lorenzo I. et al. Influence of early or late referral to nephrologist over morbidity and mortality in hemodialysis. Nefrologia 2003- 23: 234−242.
- Gawaz M.P., Mujais S.K., Schmidt B., et al. Platelet-leukocyte aggregation during hemodialysis. Kidney Int. 1994- 46:489−495.
- Geerts W., Bergqvist D., Pineo G. et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition) Chest 2008 Jun- 133(6):381−453.
- Gerlach A.T., Pickworth K.K., Seth S.K. et al. Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency. Pharmacotherapy, 2000- 20 (7):771−5.
- Goodman S.G., Menon V., Cannon C.P. et al. Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008−133:708−75.
- Gorbet M.B., Sefton M.V. Leukocyte activation and leukocyte procoagulant activities after blood contact with polystyrene and polyethylene glycol
- N immobilized polystyrene beads. J Lab Clin Med. 2001- 137:345−355.
- Gordge M.P., Leaker B.R., Patel A. et al. Recombinant human erythropoietin corrects uraemic bleeding without causing intravascular haemostatic activation. Thromb Res 1990- 57:171−182.
- Gresele P., Catalano M., Giammrresi C. et al. Platelet activation markers in patients with peripheral arterial disease — a prospective comparison of different platelet function test. Thromb Hemost 1997- 78: 1434−1437.
- Gris J.C., Branger B., Ve’cina F. et al. Increased cardiovascular risk factors and features of endothelial activation and dysfunction in dialyzed uremic patients. Kidney Int 1994- 46: 807−813.
- Haaber A.B., Eidemak I., Jensen T. et al. Vascular endothelial cell function and cardiovascular risk factors in patients with chronic renal failure. J Am Soc Nephrol 1995 Feb-5(8):1581−1584.
- Hammel F.S., Johnson G.C., Collins G.M. A critical appraisal of the changing approaches to vascular access for chronic dialysis. Proc Eur Dial Transplant Assoc 1982−19:325−330.
- Handa S.P., Colwell B. Spontaneous retropharyngeal bleeding in a patient on chronic hemodialysis. Nephron 1993−64(3):485−6.
- Harter H.R., Burch J.W., Majerus P.W. et al. Prevention of thrombosis in patients on, hemodialysis by low dose of aspirin. N Engl J' Med 1979- 301:577−579.
- Hernandez E., Praga M., Alamo C. et al. Lipoprotein (a) and vascular access survival in patients on chronic hemodialysis. Nephron 1996- 72: 145—149.
- Hirsh J., Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004- 126:188−203.i
- Hojs R., Gorenjak M., Ekart R. et al. Homocysteine and vascular access thrombosis in hemodialysis patients. Ren Fail 2002- 24: 215−222.
- Holden R.M., Harman G.J., Wang M. et al. Major bleeding in hemodialysis patients. Clin J Am Soc Nephrol 2008- 3:105−110.
- Horowitz H.I., Stein I.M., Cohen B.D., White J.G. Further studies on the platelet inhibiting effect of guanidinosuccinic acid and its role in uremic1.bleeding. Am J Med 1970- 49:336−340.
- Huang J.W., Wu M.S., Chu T.S., Tsai T.J. Hepatic aneurysm and portal vein thrombosis in a patient with lupus erythematosus on dialysis. Nephrol Dial Transplant. 1999 Mar- 14(3):753−6.
- Ignarro L.J. Endothelium-derived nitric oxide: actions and properties. Fed Am Soc Exp Biol J 1988- 3:31−36.
- Ishii Y., Yano S., Kanai Hi, Maezawa A. et al. Evaluation of bloodcoagulation-fibrinolysis system in patients receiving chronic hemodialysis. Nephron 73: 407112, 1996.
- Janson P.A., Jubelirer S. J, Weinstein M.J., Deykin D. Treatment of bleeding tendency in uremia with cryoprecipitate. N Engl J Med 1980- 303:1319−1322.
- Jun Fang, Ling-Hui Xia, Wen-Ning Wei, Shan-Jun Song Coagulation factor VII levels in uremic patients and their influence factors Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004 Dec -12 (6):730−2.
- Jungers P., Zingraff J., Page B. et al. Detrimental effects of late referral in patients with chronic renal failure: a case-control study. Kidney Int Suppl 1993- 41:170−173.
- Kay R., Wong K.S., Yu Y.L. et al. Low-molecular-weight heparin for the treatment of acute ischemic stroke. N Engl J Med 1995−333:1588−1593.
- Kazatchkine N., Sulta V., Caen J.P., Bartiery J. Bleeding in uremia: a possible cause. Br Med J 1976- 2:612−615.
- Kessler M., Frimat L., Panescu V. et al. Impact of nephrology referral on early and midterm outcomes in< ESRD: results of a 2-year prospective, community-based study. Am J Kidney Dis 2003- 42: 474−485.
- Kleinknecht D., Jungers P., Chanard J. et al. Uremic and non-uremic complications in acute renal failure. Evaluation of early and frequent dialysis on prognosis. Kidney Int 1972- 1:190−196.
- Kleta R., Frund S., Kuwertz-Broking E., Bulla M. Intraperitoneal application of low-molecular-weight heparin in continuous ambulatory peritoneal dialysis in a child. Nephron 2000−86:545.
- Knoll G., Wells P., Young D. et al. Thrombophilia and the risk for hemodialysis vascular access thrombosis. J Am Soc Nephrol 2005−16:1108−1114.
- Knudsen F., Dyerberg J. Platelets and antithrombin III in uraemia: the acute effect of haemodialysis. Scand J Clin Lab Invest 1985- 45: 341−347.
- Kooistra M. P., van Es A., Marx J. J. M. et al. Low-dose aspirin does not prevent thrombovascular accidents in low-risk haemodialysis patients during treatment with recombinant human erythropoietin. Nephrol Dial Transplant. 1994−9:1115−1120.
- Kountchev J., Bijuklic K., Bellmann R. et al. Reduction of D-dimer levels after therapeutic administration of antithrombin in acquired antithrombin deficiency of severe sepsis. Crit Care 2005- 9: 596−600.
- Kushiya F., Wada H., Sakakura M. et al. Atherosclerotic and hemostatic abnormalities in patients undergoing hemodialysis. Clin Appl Thromb Hemost. 2003 Jan-9(l):53−60.
- Lachish T., Rudensky B., Slotki I., Zevin S. Enoxaparin dosage adjustment in patients with severe renal failure: antifactor xa concentrations and safety. Pharmacotherapy 2007 Oct-27(10):1347−52.
- Landray M.J., Wheeler D.C., Lip G.Y. et al. Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis, 2004- 43: 244−53.
- Lane D.A., Flynn A., Ireland H. et al. On the evaluation of heparin and low molecular weight heparin in haemodialysis for chronic renal failure. Haemostasis. 1986−16 Suppl 2:38−47.
- LcSar C.J., Merrick H.W., Smith M.R. Thrombotic complications resulting from liypercoagulable states in chronic hemodialysis vascular access. J Am Coll Surg 1999:189:73−81. ,
- Lim W., Cook DJ., Crowther M.A. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. J Am Soc Nephrol 2004- 15(12):3192: — 206.
- Lim W., Dentali F., Eikelboom J.W., Crowther M.A. Meta-analysis:low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intent Med. 2006 May 2−144(9):673−84.
- Lim P. S., Wu M.Y., Chien S.W. et al. Elevated circulating levels of soluble CD-40 ligand in haemodialysis patients with symptomatic coronary heart disease. Nephrology (Carlton) 2008 Dec-13(8):677−83.
- Limdi N.A., Beasley T.M., Baird M.F. et all Kidney function influences, warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol. 2009 Apr-20(4):912−21.
- Lindsay R.M., Moorthy A.V., Koens F., Linton A.L. Platelet function in dialyzed and non-dialyzed patients with chronic renal failure., Clin Nephrol 1975−4:52−57.
- Lindsay R.M., Prentice C.R., Davidson J.F. et al. Hemostatic changes during dialysis associated with thrombus formation on dialysis membranes. Br Med J 1972- 4:454.
- Livio M., Gotti E., Marchesi D. et al. Uraemic bleeding: role of anemia and beneficial effect of red cell transfusions. Lancet 1982- 2:1013−1015.
- Ljungberg B. A low molecular heparin fraction as an anticoagulant during hemodialysis. Clin Nephrol. 1985 Jul-24(l): 15−20.
- Lord H., Jean N., Dumont M. et al. Comparison between tinzaparin and. standard heparin for chronic hemodialysis in a Canadian center. Am J Nephrol 2002- 22:58−66. *
- Lovenox product monograph (enoxaparin sodium).1 Aventis Pharma Inc, 2004:
- Mahe I., Gouin-Thibault I., Drouet L. et al. Elderly medical patients treated with prophylactic dosages of enoxaparin: influence of renal function on anti-Xa activity level. Drugs Aging. 2007−24(1):63−71.
- Malyszko J., Malyszko J.S., Mysliwiec M. Tissue factor pathway inhibitor and tissue factor in HD and CAPD. Nephrol Dial Transplant 1998- 13:2424−6.
- Mannucci P.M., Remuzzi G., Pusinieri F. et al. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia. N Engl J Med 1983−308:8−12.
- Mercier E., Branger B., Vecina F. et al. Tissue factor coagulation pathway and blood cells activation state in renal insufficiency. Hematol J. 2001−2(l):18−25.
- Mezzano D., Tagle R., Pais E. et al. Endothelial cell markers in chronic uremia: Relationship with hemostatic defects and severity of renal failure. ThrombRes 1997−88: 465−472.
- Mokrzycki M.H., Jean-Jerome K., Rush H. et al. A randomized trial of minidose warfarin for the prevention of late malfunction in tunneled, cuffed hemodialysis catheters. Kidney Int 2001- 59:1935−1942.
- Murakami M., Hamasaki T., Kimura S. et al. Clinical features and management of intracranial hemorrhage in patients undergoing maintenance dialysis therapy. Neurol Med Chir (Tokyo).2004 May- 44 (5):225−32- discussion 233.
- Nakamura Y., Chida Y., Tomura S. Enhanced coagulation-fibrinolysis in patients on regular hemodialysis treatment: Nephron 1991- 58: 201−204.
- Nampoory M., Das K., Johny K. et al. Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation. Am J Kidney Dis 2003−42:797−805.
- Naumnik B., Borawski J., Mysliwiec M. Different effects of enoxaparin and unfractionated heparin on extrinsic blood coagulation during haemodialysis: a prospective study. Nephrol Dial Transplant 2003- 18: 1376−1382.
- Naumnik B., Borawski J., Pawlak K., Mysliwiec M. Effect of hemodialysis on plasma levels of vascular endothelial markers. Clin Appl Thromb Hemost 2002- 8: 245−50.
- Nelson-Piercy C., Letsky E., de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: Experience of sixty-nine pregnancies in sixty-one women at high risk American Journal of Obstetrics and Gynecology 1997- 176 (5): 1062−1068.
- Nishimura M., Hashimoto T., Kobayashi H. et al. The high incidence of left atrial appendage thrombosis in patients on maintenance haemodialysis. Nephrol Dial Transplant 2003- 18: 2339−2347.
- Nurmohamed M.T., ten Cate J., Stevens P. et al. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients. A comparison with standard heparin. ASAIO Trans 1991- 37: M459-M461.
- Obialo C.I., Conner A.C., Lebon L.F. Maintaining patency of tunneled hemodialysis catheters. Scand J Urol Nephrol 2003- 37: 172−176.
- O’Brien J.R. Shear-induced platelet aggregation. Lancet 1990- 335:711−713.
- Opatrny Jr. K, Zemanova P, Mares J et al. Defect in Long-Term Hemodialysis Patients with Type 2 Diabetes mellitus and Its Relation to Metabolic Disorders Am J Nephrol 2002−22:429−436.
- Ortega T., Ortega F., Diaz-Corte C. et al. The timely construction of arteriovenous fistulae: a key to reducing morbidity and mortality and to improving cost management. Nephrol Dial Transplant 2005- 20: 598−603.
- O’Shea S.I., Lawson J.H., Reddan D. et al. Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosis. J Vase Surg 2003−38: 541−548.
- Palomo I., Pereira J., Alarcon M. et al. Vascular access thrombosis is not related to presence of antiphospholipid antibodies in patients on chronic hemodialysis. Nephron 2002- 92: 957−958.
- Pawlak K., Borawski J., Naumnik B., Mysliwiec M. Relationship between oxidative stress and extrinsic coagulation pathway in haemodialyzed patients. Thromb Res. 2003 Mar 15−109(5−6):247−51.
- Pawlak K., Naumnik B., Brzosko S. et al. Oxidative stress a link between endothelial injury, coagulation activation, and atherosclerosis in haemodialysis patients. Am J Nephrol 2004- 24:154−61.
- Pham P.T., Peng A., Wilkinson A. et al. Cyclosporine and tacrolimus-associated thrombotic microangiopathy. Am J Kidney Dis 2000- 36: 844−850.
- Poyrazoglu O.K., Dogukan A., Yalniz M. et al. Acute effect of standard heparin versus low molecular weight heparin on oxidative stress and inflammation in hemodialysis patients. Ren Fail. 2006−28(8):723−7.
- Rabelink T.J., Zwaginga J.J., Koomans IT.A., Sixma J.J. Thrombosis and hemostasis in renal failure. Kidney Int 1994: 46: 287−296.
- Rabiner S: F. Uraemic bleeding- Progress in Hemostasis andThrombosis. New York: Grune & Stratton, 1972: 233−250.
- Rajgopal R., Bear M., Butcher M: K., Shaughnessy S.G. The effects of heparin and low molecular weight heparins on bone. Thrombosis Research 2008, 122 (3), 293−298.
- Reilly R.F. The pathophysiology of. immune-mediated heparin-induced thrombocytopenia. SeminvDial. 2003- 16(1):54−60.153: Remuzzi G., Benigni A., Dodesini P. et al. Parathyroid hormone inhibits human platelet function. Lancet 1981- 2:1321−1323.
- Remuzzi G., Perico N., Zoja C. et al. Role of endothelium-derived nitric oxide in the bleeding tendency of uremia. J Clin Invest 1990- 86:1768−1771.
- Remuzzi G., Livio M., Marchiaro G. et al. Bleedingdn renal failure: altered platelet function in chronic uraemia only partially corrected by haemodialysis. Nephron 1978- 22:347−353.
- Remuzzi G., Cavenaghi A.E., Mecca G. et al. Prostacyclin-like activity and bleeding in renal failure. Tancet 1977- 2:1195−1197.
- Renaud H., Moriniere P., Dieval J. et al. Low molecular weight heparin in haemodialysis and haemofiltration—comparison with unfractioned heparin. Proc Eur Dial Transplant Assoc Eur Ren Assoc. 1985−21:276−80. .
- Riesman D- Hemorrhages in the course of Bright' disease with special reference to the occurrence of a hemorrhagic diathesis of nephritic origin. Am J Med Sci 1907- 134:709.
- Robert F. The potential’benefits of low-molecular-weight heparins in cancer patients- J Hematol Oncol. 2010- 3(3):1−12.
- Ruiz-Irastorza G., Khamashta M., Hughes G. Heparin and osteoporosis during pregnancy: 2002 update. Lupus. 2002- 11 (10): 680−2.
- Rutsky EA, Rostand SG. Treatment of uraemic pericarditis and pericardial effusion. Am J Kidney Dis 1987- 10:2−8.
- Ryan K.E., Lane D.A., Flynn A. et al. Dose finding study of a low molecular — weight heparin, Innohep, in haemodialysis. Thromb Haemost. 1991 -66: 27 782.
- Sagedal S., Hartmann A., Sundstrom K. et al. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets Nephrol. Dial. Transplant. 2001- 16(5): 987−993.
- Sagedal S., Hartmann A., Sundstrom K. et al. A single dose of dalteparin effectively prevents clotting during haemodialysis. Nephrol Dial Transplant. j1999 Aug- 14(8): 1943−7.i
- Saglikes Y., Massry S.G., Iseki K. et al. Effect of PTH on blood pressure and responseto vasoconstrictor"agonists. Am J Physiol 1985- 248:674−681.
- Sagripanti A., Cupisti A., Baicchi U. et al. Plasma parameters of the prothrombotic state in chronic uremia. Nephron. 1993−63(3):273−8.
- Santopinto J.J., Fox K.A., Goldberg R.J. et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart 2003 Sep-89(9): 1003−8.
- Saran R., Dykstra D.M., Wolfe R.A. et al. Association between vascular access failure and the use of specific drugs: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 2002−40: 1255−1263.
- Schrader J., Stibbe W., Armstrong V.W. et al. Comparison of low molecular weight heparin to standard heparin in hcmodialysis/hemofiltration. Kidney Int. 1988 Apr-33(4):890−6.
- Schrader J., Tonnis H.J., Scheler F. Long-term intraperitoneal application of low molecular weight heparin in a continuous ambulatory peritoneal dialysis patient with deep vein thrombosis. Nephron 1986−42:83−4.
- Schrader J., Valentin R., Tonnis H.J. et al. Low molecular weight heparin in hemodialysis and hemofiltration patients. Kidney Int. 1985 Nov-28(5):823−9.
- Schwenger V., Morath C., Hofmann A .et al. Late referral—a major cause of poor outcome in the very elderly dialysis patient. Nephrol Dial Transplant 2006−21:962−967.
- Shemin D., Lapane K.L., Bausserman L. et al. Plasma total homocysteine and hemodialysis access thrombosis: A prospective study. J Am Soc Nephrol 1999−10: 1095−1099.
- Shepherd A.M., Stewart W.K., Wormsley K.G. Peptic ulceration in chronic renal failure. Lancet 1973- 1:1357−1359.
- Shiao C.C., Huang J.W., Chien K.L. et al. Early initiation of dialysis and late implantation of catheters adversely affect outcomes of patients on chronic peritoneal dialysis. Perit Dial Int 2008- 28: 73−81.
- Siebels M., Andrassy K., Vecsei P. et al. Dose dependent suppression of mineralocorticoid metabolism by different heparin fractions. Thromb Res. 1992 Jun l-66(5):467−73.
- Simpson H.K.L., Baird J., Allison M. et al. Long-term use of the low molecular weight heparin tinzaparin in haemodialysis. Haemostasis 1996−26:90−7.
- Sinauridze E.I., Kireev D.A., Popenko* N.Y. et al. Platelet micrparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007 Nov-98(5): 1143−4.
- Sirolli V., Strizzi L., Stante S.D. et al. Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. Thromb Hemost 2001- 86: 834−839.
- Sloand J.A., Sloand E.M.: Studies on platelet membrane glycoproteins and platelet function during hemodialysis. J Am Soc Nephrol 1997−8:799−803.
- Slusher M.M., Hamilton R.W. Letter: spontaneous hyphema during hemodialysis. N Engl J Med 1975- 293:561.
- Smith M.C., Dunn M.J. Impaired platelet thromboxane production in renal failure. Nephron 1981- 29:133−137.
- Sobel M., Fish W.R., Torna N. et al. Heparin modulates integrin function in human platelets. J Vase Surg. 2001−33:587−94.
- Spijker H.T., Graaff R., Boonstra P.W. et al. On the influence of flow conditions and wettability on blood material interactions. Biomaterials 2003- 24:4717^1727.
- Squires J.W., Pinch L.W. Heparin-induced spinal fractures. JAMA 1979 Jun l-241(22):2417−8.
- Stefoni S., Cianciolo G., Donati G. et al. Standard heparin versus low-molecular-weight heparin. A medium-term comparison in hemodialysis. Nephron 2002- 92: 589−600.
- Susicky P, Mach R. Occlusion of the central retinal vein in hemodialyzed patients. Cas Lek Cesk. 1989 Jun 28−128(26):823−5.
- Taki K., Takayama F., Tsuruta Y., Niwa T. Oxidative stress, advanced glycation end product, and coronaiy artery calcification in hemodialysis patients. Kidney Int. 2006 Jul-70(l):218−24.
- Taylor J.E., Belch’J.J.F., McLaren M. et al. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidnev Int 1993- 44: 182−190.
- Tincani E., Mannucci C., Casolari B. et al. Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study. Haematologica 2006 Jul-91(7):976−9.
- Toborek M., Wasik T., Drozdz M. et al. Effect of haemodialysis on lipid peroxidation and antioxidant system in patients with chronic renal failure. Metabolism. 1992- 41(11): 1299−32.
- Tomura S., Nakamura Y., Deguchi F. et al. Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. Thromb Res 1991−64:81−90.
- Tomura S., Nakamura Y., Tachibana K. et al. Enhanced coagulation and fibrinolysis during treatment with recombinant human erythropoietin in patients undergoing chronic hemodialysis., Blood Purif. 1993-ll (6):370−7.
- Tsao C.J., Kao R.H., Cheng T.Y. et al. The effect of recombinant human erythropoietin on hemostatic status in chronic uremic patients. Int J Hematol. 1992 Apr-55(2): 197−203.
- Tschoepe D., Roesen P., Schwippert B., Gries F.A. Platelet in diabetes: the role in the hemostatic regulation in atherosclerosis. Semi Thromb Hemost 1993- 19: 122−128.
- Turney J.H., Fewell M., Williams L.C. et al. Paradoxical behaviour of. antithrombin III during hemodialysis and its prevention with prostacyclin. Clin Nephrol January 1982- 17 (1) — 31−35. ' '
- Turnitto W.T., Weiss H.T. Red blood cells: their dual role in thrombus formation. Science 1980- 207:541−543.
- Tveit D.P., Hshieh P., Cruess D. et al. Risk factors for pulmonary embolism in chronic dialysis patients. J Nephrol. 2002 May-Jun-15(3):241−7.
- Uchida Y. Long-term hemodialysis and changes in variables of coagulation and fibrinolysis Fukuoka Igaku Zasshi. 1991 Nov-82(l l):576−85.
- Valeri A., Joseph R., Radhakrishnan J. A large prospective survey of anti-cardiolipin antibodies in chronic hemodialysis patients.' Clin Nephrol 1999- 51: 116−121.
- Varan B., Karakayali H., Kutsal A., Ozdemir N. Spontaneous hemothorax in a hemodialysis patient. Pediatr Nephrol. 1998 Jan- 12(l):65−6.
- Vaziri N.D., Gonzales E.C., Wang J., Said S. Blood coagulation, fibrinolysis, and inhibitory proteins in end-stage renal disease: effect of hemodialysis. Am J Kid Dis 1994- 23: 828−835.
- Vigano’G., Benigni A., Mendogni D. et al. Recombinant human erythropoietin to correct uremic bleeding. Am J Kidney Dis 1991- 1:44^-9.
- Vigano’G., Gotti E., Comberti E. et al. Hyperparathyroidism does not influence the abnormal primary haemostasis in patients with chronic renal failure. Nephrol Dial Transplant 1989- 4: 971−974.
- Virchow R. Gesammelte Abhandlungen zur Wissenshaftlichen Medicin. Frankfurt, Meidinger. 1856.
- Vlachoyannis J., Schoeppe W. Adenylate cyclase activity and cAMP content of human platelets in uremia. Eur J Clin Invest 1982- 12:379−381.
- Vlassopoulos D., Noussias C., Hadjipetrou A. et al. Long-term effect of low molecular weight heparin on serum lipids in hypertriglyceridemic chronic hemodialysis patients. J Nephrol. 1997 Mar-Apr-10(2):l 11−4.
- Ware J.A., Clark B.A., Smith M., Salzman E.W. Abnormalities of cytoplasmic Ca2+ in platelets from patients with uremia. Blood 1989- 73:172−176.
- Willems C., Stel H.V., van Aken W.G., van Mourik J.A. Binding and inactivation of prostacyclin (PGI2) by human erythrocytes. Br J Haematol 1983- 54:43−52.
- Winearls C.G., Oliver D.O., Pippard M.J. et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986- 2: 1175−1178.
- Wu K.K. Platelet activation mechanisms and markers in arterial thrombosis. J IntMed 1996- 239: 17−34.
- Yang C., Wu T., Huang C. Low molecular weight heparin reduces triglyceride, VLDL and cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis. Am J Nephrol. 1998−18(5):384−90.
- Yao-Cheng C., Jin-Bor C., Lin-Cheng Y. et al. Significance of platelet activation in vascular access survival of haemodialysis patients Nephrol Dial Transplant 2003- 18: 947−954.
- Yevzlin A.S., Conley E.L., Sanchez R.J. et al. Vascular access outcomes and medication use: a USRDS study. Semin Dial. 2006 Nov-Dec-19(6):535−9.
- Zariuan A., Meleg-Smith S., O’Donovan R. et al. Cyclosporine-associated thrombotic microangiopathy in renal allografts. Kidney Int 1999- 55: 2457— 2466.